These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12003139)

  • 1. Therapeutic options in an era of decreasing antimicrobial susceptibility.
    Drlica K; Schmitz FJ
    J Chemother; 2002 Feb; 14 Suppl 2():5-12. PubMed ID: 12003139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.
    Zhao X; Drlica K
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S147-56. PubMed ID: 11524712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of several fluoroquinolones and beta-lactams in terms of their capability to restrict the selection of fluoroquinolone-resistant Salmonella: in vitro models.
    Cebríán L; Rodríguez JC; Escribiano I; Royo SG
    APMIS; 2007 Dec; 115(12):1376-82. PubMed ID: 18184408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
    Cui JC; Liu YN; Wang R; Liang BB; Pei F; Zheng ZJ
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1863-6. PubMed ID: 15631794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.
    Metzler K; Hansen GM; Hedlin P; Harding E; Drlica K; Blondeau JM
    Int J Antimicrob Agents; 2004 Aug; 24(2):161-7. PubMed ID: 15288315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-related selection of fluoroquinolone-resistant Escherichia coli.
    Olofsson SK; Marcusson LL; Strömbäck A; Hughes D; Cars O
    J Antimicrob Chemother; 2007 Oct; 60(4):795-801. PubMed ID: 17635875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.
    Blondeau JM
    Vet Dermatol; 2009 Oct; 20(5-6):383-96. PubMed ID: 20178475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mutant selection window and antimicrobial resistance.
    Drlica K
    J Antimicrob Chemother; 2003 Jul; 52(1):11-7. PubMed ID: 12805267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
    Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
    J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Widespread use of fluoroquinolones versus emerging resistance in pneumococci.
    Goldstein EJ; Garabedian-Ruffalo SM
    Clin Infect Dis; 2002 Dec; 35(12):1505-11. PubMed ID: 12471570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance?
    Fraise AP
    J Infect; 2006 Nov; 53(5):293-300. PubMed ID: 16876253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.
    Rodríguez JC; Cebrián L; López M; Ruiz M; Jiménez I; Royo G
    J Antimicrob Chemother; 2004 Mar; 53(3):441-4. PubMed ID: 14963069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in pharmacodynamic studies of antimicrobial resistance.
    Rapp RP; Campion JJ
    Ann Pharmacother; 2003 Sep; 37(9):1329-30. PubMed ID: 12921518
    [No Abstract]   [Full Text] [Related]  

  • 17. Mutant selection window hypothesis updated.
    Drlica K; Zhao X
    Clin Infect Dis; 2007 Mar; 44(5):681-8. PubMed ID: 17278059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.
    Wispelwey B
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S127-35. PubMed ID: 15942879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC; Wang HB; Sun ZY; Shen ZY
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of antimicrobial resistance in pathogenic bacteria from livestock animals.
    Wallmann J
    Int J Med Microbiol; 2006 Jun; 296 Suppl 41():81-6. PubMed ID: 16530479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.